Additionally, treatment of patients with SJIA with agents that block IL-1 signaling pathways resolves clinical symptoms with corresponding improvements in laboratory markers of inflammation [8–14]. This evidence concerns the gene IL1B and systemic-onset juvenile idiopathic arthritis.